Amphotericin B is the only broad-spectrum antifungal agent currently available for the treatment of systemic mycotic infections in man. Administered intravenously, it has been effective in the treatment of patients with histoplasmosis, North American blastomycosis, coccidiomycosis, cryptococcosis, and specific Candida infections. In addition, isolated cases of South American blastomycosis, aspergillosis, sporotrichosis, mucormycosis, and chromoblastomycosis have responded favorably. Intrathecal administration is frequently indicated in systemic fungal infections involving the central nervous system. The reversible side effects of chills, fever, nausea, vomiting, hypokalemia, anemia, and azotemia warrant necessary precautions during the administration of this agent. Simple safeguards can effectively control these manifestations and so enhance the usefulness of this potent antifungal antibiotic when used via the intravenous and intrathecal routes.
Andriole VT, Kravetz HM. The Use of Amphotericin B in Man. JAMA. 1962;180(4):269–272. doi:10.1001/jama.1962.03050170001001
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: